Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-06-26
1999-09-28
Lambkin, Deborah C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514381, 514364, A61K 31415, A61K 3141
Patent
active
059589612
ABSTRACT:
This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
REFERENCES:
patent: 4139633 (1979-02-01), Brunner et al.
patent: 4880804 (1989-11-01), Carini et al.
patent: 4895846 (1990-01-01), Poindexter et al.
patent: 5128356 (1992-07-01), Naka et al.
patent: 5162326 (1992-11-01), Naka et al.
patent: 5183899 (1993-02-01), Naka et al.
patent: 5250554 (1993-10-01), Naka et al.
patent: 5284561 (1994-02-01), Naka et al.
"Low Doses of Hydrochlorothiazide in Hypertension Antihypertensive and Metabolic Effects", G. Berglund, et al., Europ. J. Clin. Pharmacol., vol. 10, pp. 177-182 (1976).
"Antihypertensive Effect of Various Doses of Hydrochlorothiazide and its Relation to the Plasma Level of the Drug", B. Beermann, et al., Europ. J. Clin. Pharmacol., vol. 13, pp. 195-201 (1978).
"Effects if a nonpeptide angiotensin II receptor anatagonist (CV-11974) on et al., Europ. J. of Pharmacol., vol. 235, pp. 313-316 (1993).
"Antihypertensive Effects of a Highly Potent and Long-Acting Angiotensin II Subtype-1 Receptor Antagonist, (.+-.)-1-(Cyclohexyloxycarbonyloxy)ethyl -Carboxylate(TCV-116), in Various Hypertensive Rats", Inada et al., J. Pharmacol. and Experim. Therapeutics., vol. 268, No. 3, pp. 1540-1547 (1994).
"Chronic Angiotensin II (AII) Receptor Blockade Lowers Arterial Pressure (AP) and Glomerular Capillary Pressure (P.sub.GC) in Diabetic Rats" Anderson et al. American J. of Hypertension, vol. 4, 11A-12A (1991).
"Non-peptide angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor: effort on a renin-induced deficit of a passive avoidance response in rats" Denoble et al. Brain Research, vol. 561, pp. 230-235 (1991).
"Quantitive Autoradiography Reveals Different Angiotensin II Receptor Subtypes in Selected Rat Brain Nuclei" Tsutsumi et al. J. of Neurochem., vol. 56, No. 1, pp. 348-351 (1991).
"TCV-116, a Novel Angiotensin II Receptor Antagonist, Prevents Intimal Thickening and Impairment of Vascular Function after Carotid Injury in Rats" Kawamura et al., J. Pharmacol. and Experim. Therapeutics, vol. 266, No. 3, pp. 1664-1669 (1993).
"Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone" Wada et al., Eur. J. Pharmacol., vol. 253, pp. 27-34 (1994).
"Involvement of the Renin-Angiotensin System in Ischemic Damage and Reperfusion Arrhythmias in the Isolated Perused Rat Heart", Fleetwood et al., J. Cardiovasc. Pharmacol., vol. 17, pp. 351-356 (1991).
Inada Yoshiyuki
Kubo Keiji
Lambkin Deborah C.
Takeda Chemical Industries Ltd.
LandOfFree
Pharmaceutical composition for angiotensin II-mediated diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition for angiotensin II-mediated diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition for angiotensin II-mediated diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703840